GET DAILY SIGNALSAtriCure (ATRC) Delivers +15% Revenue Growth in Q3 2026 and Returns to Profitability
Key Takeaways
- Third-quarter 2026 revenue reached $154.5 million, up 15% year over year and ahead of the roughly $151 million consensus estimate.
- AtriCure returned to profitability, posting net income of $4.1 million versus a net loss of $0.3 million in the prior-year quarter.
- Adjusted earnings per share (EPS) came in at $0.18, a sharp improvement from an adjusted loss of $0.01 a year earlier.
- Adjusted EBITDA rose 50.6% to $26.8 million.
- U.S. pain management and open ablation franchises led the way, growing 34.6% and 20.8%, respectively.
- Management raised its full-year 2026 revenue outlook to a range of $606 million to $610 million.
Why This Quarter Matters for AtriCure
AtriCure focuses on surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain relief. The third-quarter 2026 results provide a useful test of whether the company can maintain double-digit revenue growth while building sustainable profitability. After two quarters of positive performance and a return to GAAP net income, this report offered confirmation on whether pain management and open ablation could offset softness in minimally invasive ablation. It also served as a checkpoint for the updated full-year outlook and progress on the BoxX-NoAF clinical trial.
The Reported Numbers
AtriCure posted third-quarter 2026 worldwide revenue of $154.5 million, a 15% increase year over year, or 15.1% in constant currency, which topped consensus estimates near $151 million. U.S. revenue rose 17.1% to $128 million, while international revenue increased 5.8% to $26.4 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Growth appeared across most core areas. U.S. pain management revenue jumped 34.6% to $28.1 million, helped by cryoSPHERE MAX and cryoXT. U.S. open ablation advanced 20.8% to $43 million, driven by the EnCompass Clamp. U.S. appendage management climbed 13.5% to $51.6 million with greater use of AtriClip FLEX-Mini and PRO-Mini devices. Minimally invasive ablation stayed the weaker segment, falling 27.5% to $5.4 million amid a shift toward pulsed field ablation therapies.
Profitability showed clear progress. Net income reached $4.1 million compared with a $0.3 million loss a year earlier. GAAP diluted EPS was $0.08 versus a loss of $0.01, and adjusted EPS of $0.18 exceeded expectations that had pointed to roughly breakeven. Gross margin widened 180 basis points to 77.3%, and adjusted EBITDA increased 50.6% to $26.8 million. The company finished the quarter with $187 million in cash and investments after generating $19.2 million in cash flow.
Management lifted its full-year 2026 revenue guidance to approximately $606 million to $610 million, which implies annual growth of about 13.4% to 14.1%.
How the Market Responded
Heading into the release, sentiment around AtriCure had been positive after sharp gains over the prior three and twelve months. The company delivered a solid beat on revenue and earnings, supported by faster growth in pain management and open ablation plus wider margins. Yet early after-hours trading showed some pressure on the stock, which may reflect investor focus on the continued decline in minimally invasive ablation, higher research and development costs linked to the BoxX-NoAF trial, or a valuation that already reflected much of the strength. The raised full-year guidance offered a positive signal, though the measured reaction highlights how high expectations can influence post-earnings moves even after good results.
What to Watch Going Forward
Investors will track several upcoming catalysts tied to the clinical pipeline and product lineup. The BoxX-NoAF trial, which examines prevention of post-operative atrial fibrillation in cardiac surgery patients, has enrolled more than 880 participants. Management expects enrollment to finish by the end of 2026, with initial primary-endpoint data expected in spring 2027. That data could shape the longer-term growth story.
On the product side, AtriCure recently obtained FDA 510(k) clearance for a 30-millimeter AtriClip FLEX-Mini device and plans a December launch to strengthen its left atrial appendage management offering. Progress with cryoXT in pain management and the expected late-2027 introduction of AtriClip FLEX-Mini V are also worth following.
At the same time, the ongoing drop in minimally invasive ablation and softness in some international markets remain areas to monitor. Margin trends will stay in focus given favorable product and geographic mix, costs from the new manufacturing facility, and higher clinical spending. The updated full-year revenue range of $606 million to $610 million provides a clear benchmark for execution through year-end.
AI Tools in My Research Process
From what I see, tools like Tickeron’s AI Screener help surface comparable setups in the medical-device space when evaluating names like AtriCure. It allows filtering by technical patterns, fundamentals, and performance metrics to identify potential trade ideas more efficiently than manual methods alone. I find it useful for placing individual results in a broader market context without replacing core fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ATRC's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Oscillator for ATRC moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 instances where the indicator moved out of the overbought zone. In 25 of the 30 cases the stock moved lower in the days that followed. This puts the odds of a move down at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATRC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ATRC as a result. In 63 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ATRC just turned positive on October 23, 2026. Looking at past instances where ATRC's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
Following a +4.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATRC advanced for three days, in 214 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
ATRC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 147 of 222 cases where ATRC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ATRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.898) is normal, around the industry mean (4.877). ATRC's P/E Ratio (272.182) is considerably higher than the industry average of (37.682). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.869) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of surgical and medical instruments
Industry PharmaceuticalsOther
Advertisement